Interestingly, we found that CTLA4, HAVCR2, PD-L1, PD-1 and TIGIT were significantly higher in the high CRGs-score group, indicating that HCC in cuproptosis status might be sensitive to immune checkpoint blockade therapies (p < .05, Figure 7C). The gene discussed is HAVCR2; the disease is hepatocellular carcinoma.